^^name=Raloxifene
^^width=320
^^IUPAC= />3-yl -[4-[2-(1-piperidyl)ethoxy]phenyl]-methanone
^^synonyms=Keoxifene Raloxifenum (Latin)
^^abbreviations=RAL
^^formula=C 28H 7NO 4S
^^mass=473.584
^^density=?
^^Tm=?
^^Tb=?
^^pKa=?
^^accept=5
^^donor=2
^^tautomers=12
^^CAS=
^^EINECS=?
^^PubChem=5035
|
is an oral
Selective Estrogen Receptor Modulator which is used in the prevention of
Osteoporosis in postmenopausal women. It was announced on
April 17 ,
2006 , that raloxifene is as effective as
Tamoxifen in reducing the incidence of
Breast Cancer , but with fewer side effects.
[http://ca.today.reuters.com/news/newsArticle.aspx?type=topNews&storyID=2006-04-18T001012Z_01_N17276340_RTRIDST_0_NEWS-CANCER-BREAST-COL.XML&archived=False However, it has not been approved by the FDA for this use.
Raloxifene is produced by
Eli Lilly Pharmaceuticals and is sold under the brand name .
SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as
Pfizer's Lasofoxifene and
Wyeth's Bazedoxifene are in the late stages of clinical development.
